Literature DB >> 7399748

Malignant melanoma in Connecticut and Denmark.

A Houghton, J Flannery, M V Viola.   

Abstract

The rising incidence of malignant melanoma of the skin was reviewed using data from the Connecticut Tumor Registry (1935-1974) (Eisenberg et al., 1967) and the Danish Cancer Registry (1942-1972) (Clemmesen, 1965, 1974, 1977). A total of 7,530 cases were analyzed according to age, sex and anatomic site. The total age-adjusted incidence rates were similar for these two countries, despite geographic and demographic differences. HOwever, the most rapid changes in melanoma incidence were observed in females from Denmark and males from Connecticut. In addition, the largest increases occurred for lower-extremity lesions in Danish middle-aged women and trunk-neck melanomas in Connecticut middle-aged men. Melanoma of the face was resistant to changing incidence and occurred in an older age group than melanoma of other skin sites. In general, birth cohort analysis confirmed that changing incidence began for persons born around 1900, but the rising incidence for lower-extremity melanomas in women and trunk-neck melanomas in males began earlier. In comparing incidence for anatomic sites by correcting for surface area and melanocyte density, higher than expected rates were seen for melanoma of the face in both sexes and trunk-neck melanoma in the males. The data presented support the concept that a cumulative exposure to solar radiation may be important in the etiology of melanoma of the face, but short-, intense sun exposure is probably related to melanoma in other sun-exposed areas, and that melanoma in areas other than the face is responsible for the rising incidence of this disease.

Entities:  

Mesh:

Year:  1980        PMID: 7399748     DOI: 10.1002/ijc.2910250113

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

Review 1.  Cutaneous malignant melanoma and ultraviolet radiation: a review.

Authors:  J Longstreth
Journal:  Cancer Metastasis Rev       Date:  1988-12       Impact factor: 9.264

2.  Increased incidence of malignant melanoma of the skin in workers in a telecommunications industry.

Authors:  L De Guire; G Theriault; H Iturra; S Provencher; D Cyr; B W Case
Journal:  Br J Ind Med       Date:  1988-12

3.  Fibroblasts from patients with hereditary cutaneous malignant melanoma are abnormally sensitive to the mutagenic effect of simulated sunlight and 4-nitroquinoline 1-oxide.

Authors:  J N Howell; M H Greene; R C Corner; V M Maher; J J McCormick
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

4.  Malignant melanoma incidence in Connecticut (United States): time trends and age-period-cohort modeling by anatomic site.

Authors:  Y T Chen; T Zheng; T R Holford; M Berwick; R Dubrow
Journal:  Cancer Causes Control       Date:  1994-07       Impact factor: 2.506

5.  Cutaneous malignant melanoma in Hawaii--an update.

Authors:  M W Hinds; L N Kolonel
Journal:  West J Med       Date:  1983-01

6.  Period and cohort factors in the incidence of malignant melanoma in the state of Connecticut.

Authors:  J J Collins; N Devine
Journal:  Environ Health Perspect       Date:  1984-06       Impact factor: 9.031

7.  Epidemiology of melanoma of the eye in the Oxford Region, 1952-78.

Authors:  A J Swerdlow
Journal:  Br J Cancer       Date:  1983-02       Impact factor: 7.640

8.  Seasonality of presentation of cutaneous melanoma, squamous cell cancer and basal cell cancer in the Oxford Region.

Authors:  A J Swerdlow
Journal:  Br J Cancer       Date:  1985-12       Impact factor: 7.640

9.  Trends in tumour characteristics and survival of malignant melanoma 1960-84: a population-based study in Sweden.

Authors:  M Thörn; F Pontén; R Bergström; P Sparén; H O Adami
Journal:  Br J Cancer       Date:  1994-10       Impact factor: 7.640

10.  The relationship of malignant melanoma, basal and squamous skin cancers to indoor and outdoor work.

Authors:  V Beral; N Robinson
Journal:  Br J Cancer       Date:  1981-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.